Hyderabad, India
Hyderabad, India

Time filter

Source Type

Ratna Sudha M.,Unique Biotech Ltd | Bhonagiri S.,Medipoint Hospital Pvt. Ltd. | Asin Kumar M.,Government LTMG Hospital
Beneficial Microbes | Year: 2012

This study was conducted to evaluate the efficacy and safety of Saccharomyces boulardii strain Unique 28 in patients suffering from acute diarrhoea. A total of 25 patients (average age 30.72±4.38 years) with symptoms of acute diarrhoea (≥3 loose motion in last 24 hours for <7 days) were included upon informed consent and ethical committee approval. All subjects were assigned to consume S. boulardii strain Unique 28 (5×109 cfu/capsule) twice a day for a duration of 10 days. Primary outcome measures such as duration of diarrhoea, frequency of defaecation, abdominal pain and consistency of stool were analysed on day 1, 3, 6 and 10 of the study. Secondary outcome measures were evaluated by assessment of incidence and type of adverse events (blood pressure and pulse rate), physical examination and clinical laboratory tests (complete blood count, glutamic-pyruvic transaminase, serum creatinine, stool examination and microscopy and these tests were performed on day 1 and 10 of the study. The results of the present study indicate that the mean duration of diarrhoea decreased from 34.20±4.25 to 9.40±3.00 (P<0.0001) min per day, frequency of defaecation decreased from 7.04±0.84 to 1.76±0.52 (P<0.0001) times a day, abdominal pain decreased from 3.28±1.06 (severe) to 0.72±0.50 (absent) (P<0.0001) and consistency of stool improved from 3.80±0.50 (watery) to 1.32±0.47 (soft) (P<0.0001). In addition, no significant changes in safety parameters were observed during treatment. Therefore, the present study concludes that S. boulardii strain Unique-28 might be useful in alleviating the symptoms of diarrhoea without any adverse effects. © 2012 Wageningen Academic Publishers.


Sudha R.M.,Unique Biotech Ltd | Bhonagiri S.,Medipoint Hospital Pvt. Ltd.
International Journal of Probiotics and Prebiotics | Year: 2012

The objective of this study was to evaluate the efficacy and safety of Bacillus coagulans strain Unique IS-2 in the treatment of patients with acute diarrhea. To this end, a total of 28 patients with acute diarrhea were included in a prospective, phase II clinical study upon obtaining consent and ethical committee approval. The trial was performed on patients of both sexes between 18 to 55 years of age and having > 3 loose motions in last 24 hours for less than7 Days. All patients were assigned to receive capsule (containing 2 billion CFU of Bacillus coagulans strain Unique IS-2) two times daily for a duration of 10 days. Efficacy was evaluated by assessment of duration of diarrhea (in minutes) frequency of defecation (times per day), abdominal pain (3=severe; 2=moderate; l=mild; 0=absent) and consistency of stool (1=normal, 2=hard, 3= semi liquid, and 4=loose). Safety aspects of capsule were evaluated by assessment of incidence, type of adverse events, physical examination, and clinical laboratory test values (CBC, SGPT, serum creatinine, stool routine and microscopy). Concomitant medications including rescue medications were monitored throughout the study. Efficacy assessment for duration of diarrhea, frequency of defecation, abdominal pain, consistency of stool and fever was done on 1, 3, 6 and 10 days. Mean values for, duration of diarrhea decreased from 35.60 ß 5.46 to 3.52 ß 2.69 min per day, frequency of defecation was decreased from 7.96 ß 3.89 to 0.76 ß 0.60 times per day, abdominal pain decreased from 3.16 ß 0.99 to 0.36 ß 0.49 and consistency of stool improved from 3.84 ß 0.55 to 1.00 ß 0.00. No significant change in safety parameters was observed during treatment. This trial demonstrates that utilization of B. coagulans Unique IS-2 strain is efficient and safe to treat the patients with acute diarrhea.


Ratna Sudha M.,Unique Biotech Ltd | Maurya A.K.,Government LTMG Hospital
Beneficial Microbes | Year: 2012

Bacterial vaginosis (BV) is a common condition affecting millions of women annually and is characterised by a reduction in native lactobacilli. Antimicrobial therapy used to cure the disease is often found to be ineffective. We postulate that the potential probiotic capsule UB-01BV might be efficient in the treatment of BV. In the present study, 30 Indian women diagnosed with BV presenting symptoms such as white discharge, pH greater than 4.7, increased discharge, odour, colour of discharge and pruritus were included. All subjects were assigned to receive two potential probiotic capsules UB-01BV a day for 7 days. At the end of the treatment all subjects showed significant (P<0.001) positive response as revealed by a reduction in vaginosis symptoms. Therefore, the results of the present study provide the first preliminary evidence that the potential probiotic capsule UB-01BV can exert a significant reduction in vaginal infection. © 2012 Wageningen Academic Publishers.


Sudha R.M.,Unique Biotech Ltd | Sunita M.,Unique Biotech Ltd | Sekhar B.M.,Unique Biotech Ltd
International Journal of Probiotics and Prebiotics | Year: 2011

Probiotics are vital bacteria that colonize the intestine and modify its microbialflora with benefits for the host. Food products containing lactic acid bacteria have been available in the market including health supplements. However, there is not much information available regarding the toxicity of probiotic bacteria present in such preparations. In the present study acute and sub-acute oral toxicity of a new probiotic strain, Bacillus coagulans Unique IS-2 (MTCC-5260) was conducted in Sprague Dawley rats. The rats were orally fed with a single dose of 3250 and 6500 mg/kg b.w/day (5×109 spores/g in water) dose of test organism for acute and sub-acute toxicity studies respectively. While the experimental rats received doses of 130, 650, 1300 mglkg b.w/day (5×109 spores/g) for 14 consecutive days, other control animals received only water. The follow up study was carried out till 28 days. The results of this toxicity assessment indicate that there were no treatment related changes such as clinical signs, bodyweight, food intake, parameters pertaining to urine, hematological examinations, clinical chemistry, gross pathology and histopathology exhibited by experimental rats at both time intervals. Strain B. coagulans Unique IS-2 did not exhibit any clinical symptoms up to 1300 mglkg b. w dose (5×109 CFU/gram), when administered for 14 days which was considered as 'No Observed Adverse Effect Level' (NOAEL). These results suggest that the strain B. coagulans Unique IS-2 may be considered as a non-pathogenic and safe for human consumption. Copyright © 2011 by New Century Health Publishers, LLC.


Strains of Saccharomyces boulardii, a probiotic yeast, have been found to be effective in the treatment of diarrhoea, inflammatory bowel disease, irritable bowel syndrome and other conditions. In the present study, Unique 28, a strain of S. boulardii isolated and characterised in our laboratory, was evaluated for its safety assessment. Acute and sub-acute toxicity tests were performed in rats. The dose of Unique 28 (5×109 cfu/g) fed orally was, up to 6,500 mg per kg of b.w. (body weight) for acute toxicity and up to 1,300 mg per kg of b.w. for sub-acute toxicity studies. This dose was well tolerated and there was no morbidity or any kind of toxic clinical symptoms displayed either in male or female rats. Moreover, the results of sub-acute toxicity studies using Unique 28 administered for 14 weeks indicated that there were no clear unwanted treatment related effects. Overall results of this toxicology assessment indicate that Unique 28 is safe for human consumption. © 2011 Wageningen Academic Publishers.


Sudha M.R.,Unique Biotech Ltd | Sawant P.,Ltm Medical College And Hospital
Beneficial Microbes | Year: 2011

The objective of this research was to study the efficacy and safety of capsule 'UB03' to treat patients with Irritable Bowel Syndrome (IBS). Thirty patients with Rome II IBS were assigned to receive capsule 'UB03' (10 billion lyophilised bacteria and yeast/capsule produced by Unique Biotech Limited, India) twice daily for 90 days. Assessment of IBS was carried out according with Rome II criteria and their severity for 90 days of treatment with an interval of 30 days. Complete haemogram, serum glutamic pyruvic transaminase, serum creatinine were performed as a part of safety evaluation at the time of inclusion and after 90 days of treatment. There was significant improvement in frequency of defecation (23%), consistency of stool, abdominal discomfort, bloating and flatulence. However, there was no significant change in abdominal pain and mucus in stool. This trial demonstrates that the consumption of capsule 'UB03' containing potential probiotic strains is found to be effective and safe for the treatment of patients with IBS. © 2011 Wageningen Academic Publishers.


Upadrasta A.,Unique Biotech Ltd | Madempudi R.S.,Unique Biotech Ltd
Integrated Blood Pressure Control | Year: 2016

Gut microbiota play a significant role in host metabolic processes, and recent metagenomic surveys have revealed that they are involved in host immune modulation and influence host development and physiology (organ development). Initially, probiotics are identified as potential therapeutics to treat gastrointestinal disorders and to revitalize the disturbed gut ecosystem. Currently, studies are exploring the potential for expanded uses of probiotics for improving the health conditions in metabolic disorders that increase the risk of developing cardiovascular diseases such as hypertension. Further investigations are required to evaluate targeted and effective use of the wide variety of probiotic strains in various metabolic disorders to improve the overall health status of the host. This review addresses the causes of hypertension and the hypotensive effect of probiotics, with a focus on their mechanistic action. © 2016 Upadrasta and Madempudi.


Trademark
Unique Biotech Inc. | Date: 2010-11-24

Paper cups; paper lunch boxes; paper bowls; paper plates; paper trays; paper cup covers; paper dinnerware; disposable dinnerware, namely, lunch boxes, bowls and cups.


Trademark
Unique Biotech Inc. | Date: 2010-11-19

Tableware, namely, knives, forks and spoons.


Trademark
UNIQUE BIOTECH Ltd and Pharmacenter Corporation | Date: 2011-05-24

Bacillus and other microbes suspended in powdered or liquid form for sanitation, odor control and wastewater treatment applications; Bacteria for use in food manufacture. Probiotic animal feed.

Loading Unique Biotech Ltd collaborators
Loading Unique Biotech Ltd collaborators